stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) Total debt
Arrowhead Pharmaceuticals, Inc.'s total debt at the end of fiscal 2025 was $254.9M, down 35.2% from $393.2M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $864.1M. Over the past ten years it has ranged from $540.8K (fiscal 2015) to $393.2M (fiscal 2024); the current reading is higher than 80% of that period. Arrowhead Pharmaceuticals, Inc. ranks 15th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $254.9M | (35.17%) |
| FY2024 | $393.2M | 2.53% |
| FY2023 | $383.5M | 370.11% |
| FY2022 | $81.6M | 219.34% |
| FY2021 | $25.5M | 20.85% |
| FY2020 | $21.1M | 809.16% |
| FY2018 | $2.3M | (8.23%) |
| FY2017 | $2.5M | (7.12%) |
| FY2016 | $2.7M | 404.40% |
| FY2015 | $540.8K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $864.1M | (1.99%) |
| Mar 2026 | $881.6M | 334.04% |
| Dec 2025 | $203.1M | (20.31%) |
| Sep 2025 | $254.9M | 6.05% |
| 35 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. | $864.1M |
| CAI Caris Life Sciences,�Inc. compare | $393.3M |
| SYRE Spyre Therapeutics, Inc. compare | $387.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $341.3M |
| CYTK Cytokinetics, Incorporated compare | $174.4M |
| TWST Twist Bioscience Corporation compare | $15.0M |
| KRYS Krystal Biotech, Inc. compare | $8.3M |
| CORT Corcept Therapeutics Incorporated compare | $5.0M |
| PTGX Protagonist Therapeutics, Inc. compare | $1.8M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ARWR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement